National Research Corporation (NRC)
NASDAQ: NRC · Real-Time Price · USD
16.67
+0.60 (3.73%)
Jun 27, 2025, 4:00 PM - Market closed
National Research Market Cap
National Research has a market cap or net worth of $379.83 million as of June 27, 2025. Its market cap has decreased by -38.03% in one year.
Market Cap
379.83M
Enterprise Value
443.12M
1-Year Change
-38.03%
Ranking
Category
Stock Price
$16.67
Market Cap Chart
Since December 1, 1998, National Research's market cap has increased from $43.70M to $379.83M, an increase of 769.18%. That is a compound annual growth rate of 8.47%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Jun 26, 2025 | 368.90M | -10.92% |
Dec 31, 2024 | 414.10M | -57.38% |
Dec 29, 2023 | 971.50M | 5.48% |
Dec 30, 2022 | 921.00M | -12.83% |
Dec 31, 2021 | 1.06B | -2.32% |
Dec 31, 2020 | 1.08B | -34.17% |
Dec 31, 2019 | 1.64B | 73.99% |
Dec 31, 2018 | 944.40M | -32.45% |
Dec 29, 2017 | 1.40B | 33.39% |
Dec 30, 2016 | 1.05B | 36.40% |
Dec 31, 2015 | 768.40M | 20.06% |
Dec 31, 2014 | 640.00M | -26.24% |
Dec 31, 2013 | 867.70M | 133.57% |
Dec 31, 2012 | 371.50M | 42.34% |
Dec 30, 2011 | 261.00M | 14.32% |
Dec 31, 2010 | 228.30M | 65.55% |
Dec 31, 2009 | 137.90M | -28.88% |
Dec 31, 2008 | 193.90M | 3.58% |
Dec 31, 2007 | 187.20M | 19.69% |
Dec 29, 2006 | 156.40M | 28.83% |
Dec 30, 2005 | 121.40M | 4.93% |
Dec 31, 2004 | 115.70M | -1.78% |
Dec 31, 2003 | 117.80M | 72.73% |
Dec 31, 2002 | 68.20M | 54.30% |
Dec 31, 2001 | 44.20M | 57.30% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 711.28B |
Johnson & Johnson | 366.40B |
AbbVie | 327.47B |
Novo Nordisk | 301.06B |
UnitedHealth Group | 273.97B |
Abbott Laboratories | 239.05B |
Novartis AG | 231.01B |
AstraZeneca | 216.45B |